Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 75

Anrikefon Injection for Postoperative Pain After Laparoscopic Gastrectomy in Gastric Cancer

Official title: Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy

Run by Tianjin Medical University Cancer Institute and Hospital · NCT07330063 · Data updated 2026-11-12

This trial tests whether Anrikefon given by IV can reduce pain after totally laparoscopic distal gastrectomy for gastric cancer.

More Postoperative Analgesia trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment114 (estimated)
SponsorTianjin Medical University Cancer Institute and Hospital
Academic / other
Locations1 site (Tianjin, Tianjin Municipality)
StatusRecruiting
StartedApril 8, 2026
Main results expectedDecember 30, 2026
Study endsDecember 30, 2026
Registry record updatedSeptember 22, 2026
Trial IDNCT07330063 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–75 with gastric cancer scheduled for elective totally laparoscopic distal gastrectomy, ASA I–III, BMI 18–30, and who can receive PCIA.

Probably not a fit

Patients who do not respond to Anrikefon or those with contraindications to kappa agonists may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, investigator-initiated trial evaluates the safety and efficacy of Anrikefon, a peripherally acting kappa opioid receptor agonist, for postoperative analgesia after total laparoscopic distal gastrectomy. Participants are adults with gastric cancer, undergoing elective surgery, and are randomized to receive Anrikefon either as an IV bolus or infusion or to placebo. The study will monitor pain scores, analgesic use, and adverse events to determine whether Anrikefon provides better pain relief with fewer central opioid-related side effects. The trial is conducted at Tianjin Medical University Cancer Institute and Hospital.

Why it matters

Potential benefit: If successful, patients may experience better pain control with fewer headaches, nausea, and sedation after surgery.

How similar studies have gone: Prior Phase 3 trials in other settings showed analgesic benefit with a favorable safety profile for Anrikefon and reduced PONV.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged between 18 and 75 years old (inclusive).
* American Society of Anesthesiologists (ASA) physical status classification Class I-III.
* Body Mass Index (BMI) ranging from 18 kg/m² to 30 kg/m² (inclusive).
* Patients scheduled for elective total laparoscopic distal gastrectomy for gastric cancer under general anesthesia, with surgical duration \< 5 hours.
* Surgical incision length \< 8 cm.
* Voluntarily agree to participate in the trial and sign the informed consent form.

Exclusion Criteria:

* Patients undergoing emergency surgery or suffering from trauma.
* Patients who undergo conversion to open surgery or laparoscopically assisted distal gastrectomy for gastric cancer during the operation.
* Patients who refuse to receive Patient-Controlled Intravenous Analgesia (PCIA).
* Patients with a history of prior abdominal surgery.
* Patients expected to require prolonged endotracheal intubation after surgery.

Where it's running

  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting

Study contacts

  • Principal investigator: Han Liang, MS — Tianjin Medical University Cancer Institute and Hospital
  • Study coordinator: Bin Ke
  • Email: binke@tmu.edu.cn
  • Phone: 022-23340123-1061

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.